Palatin Technologies, Inc. — Form 10-Q summary
Reporting period: Three months ended September 30, 2023, Palatin’s fiscal first quarter of fiscal 2024. The filing was signed November 14, 2023. The request metadata’s “2023 Q1” label does not match the filing’s reporting period.
Business context and financial results
Palatin is a biopharmaceutical company that markets Vyleesi (bremelanotide) in the United States for premenopausal women with hypoactive sexual desire disorder and develops drug candidates targeting melanocortin receptors. Its disclosed pipeline includes PL9643 for dry eye disease (Phase 3), PL8177 for ulcerative colitis (Phase 2), and a melanocortin agonist program for diabetic nephropathy (Phase 2).
| Metric | Three months ended Sep. 30, 2023 | Prior-year comparable period |
|---|---|---|
| Net product revenue | $2.106 million | $0.870 million |
| Operating loss | $6.109 million | $8.753 million |
| Net loss | $5.888 million | $8.255 million |
| Net loss per share, basic and diluted | $0.48 | $0.86 |
| Cash used in operating activities | $5.906 million | $8.581 million |
Revenue rose approximately 142%, which management attributed to a 100% increase in sales volume and lower product allowances as a percentage of gross sales. Gross product sales were $4.587 million, offset by $2.481 million of allowances. Cost of products sold was zero, versus $86,496 a year earlier, because the 2023-period sales were from fully reserved inventory; therefore, reported product economics should be interpreted in that context.
Research and development expense fell to $5.015 million from $6.027 million, primarily due to lower spending on melanocortin receptor programs. Selling, general and administrative expense declined to $3.200 million from $3.509 million. Other income, net, was $220,498 versus $497,263; the decrease mainly reflected smaller unrealized foreign-currency gains. The filing does not present a conventional gross-margin measure.
Liquidity, balance sheet, and material changes
At September 30, 2023, cash and cash equivalents were $5.525 million, with no marketable securities remaining; current assets were $9.805 million and current liabilities were $13.610 million. Total assets were $11.247 million and total liabilities were $16.136 million. The resulting working-capital deficit was approximately $3.804 million, and stockholders’ equity was reported as a $4.889 million deficiency. Cash declined $2.465 million during the quarter. No material conventional borrowings are disclosed; liabilities include operating and finance leases and substantial manufacturing-related commitments.
Inventory increased to $1.598 million from $526,000, including $1.014 million of work-in-process. Accounts receivable decreased to $1.349 million from $2.916 million. The company reported $6.711 million of inventory purchase commitments, including $3.753 million current and $2.027 million long-term amounts accrued for estimated losses on firm commitments. Management also disclosed contractual lease obligations.
In October 2023, after quarter-end, Palatin completed an equity and warrant offering that generated net proceeds of $4.574 million. The financing included common shares, pre-funded warrants, and warrants to purchase additional common shares, and is dilutive if exercised. During the quarter, the at-the-market program generated $531,369 of net proceeds from sales of 217,027 shares.
Outlook, risks, and unusual items
Management stated that, based on available cash and the October financing, existing resources were expected to fund current operating plans into the first half of calendar 2024. Nevertheless, management concluded that substantial doubt exists about Palatin’s ability to continue as a going concern for one year from issuance of the financial statements. Additional financing or expense reductions may be necessary; absent adequate funding, the company may curtail programs or commercialization, pursue a strategic transaction, or cease operations. No specific revenue, earnings, or cash-flow guidance is provided.
Management cited Vyleesi commercialization and development spending needs, clinical and regulatory uncertainty, manufacturing and supply obligations, and dependence on future financing, licensing, or collaboration income. Vyleesi licensees in China and Korea may generate future milestones and royalties, but regulatory approval and commercialization timing are uncertain. The Lonza manufacturing agreement runs through June 30, 2024; Palatin said it intends to seek an extension and is evaluating alternative manufacturers.
Palatin disclosed it was not in compliance with NYSE American stockholders’ equity listing standards. It timely submitted a compliance plan; exchange acceptance was not assured, and failure to regain compliance could lead to delisting. The company reported no current material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of September 30, 2023.
Most important facts for investors to verify
- Whether Palatin can raise additional capital and extend its stated operating runway beyond the first half of calendar 2024, given the going-concern uncertainty.
- NYSE American’s decision on the compliance plan and the company’s progress toward required stockholders’ equity standards.
- Vyleesi sales trends, sales allowances, and the sustainability of revenue growth, particularly given zero reported cost of products sold due to fully reserved inventory.
- PL9643 Phase 3 timing and results, along with progress and funding needs for PL8177 and the diabetic nephropathy program.
- Manufacturing commitments, inventory requirements, and the resolution of the Lonza supply arrangement after June 30, 2024.
- A balance-sheet inconsistency: the balance sheet reports accumulated deficit of $421.384 million, while the statement of changes in equity reports $421.424 million; the latter also appears to reconcile to the reported total equity deficiency. Verify the correct figure in the filed financial statements.